-
NHSA and MoF Announce Medical Insurance Fund Prepayment Initiative to Aid Healthcare Institutions
•
The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MoF) have jointly issued a notification regarding the implementation of a medical insurance fund prepayment initiative. This program is designed to provide financial relief to designated medical institutions by prepaying a portion of the medical insurance fund, thereby easing…
-
InnoCare Pharma Reports 29.8% Revenue Increase in Q3 2024 Financials
•
Beijing-based biotech InnoCare Pharma (HKG: 9969; SHA: 688428) has released its financial report for the third quarter of 2024, ending September 30, 2024, along with operational updates. The company reported revenue of RMB 698 million (USD 96.9 million) for the first three quarters, marking a 29.8% increase over the same…
-
Triton Partners Mulls Acquisition of Germany’s Evotec SE, Shares Soar 22%
•
Private equity firm Triton Partners is reportedly contemplating the acquisition of Germany-based Evotec SE (NASDAQ: EVO), as per information from Reuters. This news catalyzed a 22% surge in Evotec’s shares on Monday, reflecting market anticipation of the potential deal. Triton’s Interest and ShareholdingTriton Partners has been in the process of…
-
GenScript Biotech Expands in Australia with New Sydney Operations and Logistics Center
•
GenScript Biotech Corporation (HKG: 1548), a leading Chinese biotechnology company, has announced the establishment of a new operations site and logistics center in Sydney, Australia. This strategic move highlights GenScript’s commitment to supporting the burgeoning biotechnology sector in Australia. Sydney Facility’s Role in Streamlining OperationsThe new Sydney facility is designed…
-
Leman Biotech Secures Over USD 13.9 Million in Series A Financing for Next-Gen Cancer Immunotherapies
•
China-based Leman Biotech Co., Ltd. has reportedly completed the first closing of its Series A financing round, raising over RMB 100 million (USD 13.9 million). The round was led by Fuho Capital, with additional contributions from Jun Yi Investment and AI-driven drug R&D leader XtalPi. The funds will be directed…
-
Biocytogen’s First-in-Class B7H3/PTK7 Bispecific ADC Option Exercised by IDEAYA Biosciences
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced that its US partner IDEAYA Biosciences Inc. (NASDAQ: IDYA) has exercised its option for an exclusive worldwide license for Biocytogen’s IDE034. This potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) represents a significant step forward in…
-
Gan & Lee’s GZR18 Shows Significant Weight Loss in Phase IIb Study at ObesityWeek 2024
•
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the oral presentation of results from the Phase IIb study for its glucagon-like peptide-1 (GLP-1) receptor agonist, GZR18, at ObesityWeek 2024. The drug is administered once per week and targets the obese or overweight Chinese population. Study Design…
-
J&J’s Nipocalimab Receives FDA Breakthrough Therapy Designation for Sjögren’s Disease
•
US-based pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that it has received Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration (FDA) for its investigational drug nipocalimab. The designation is for the treatment of moderate-to-severe Sjögren’s disease (SjD), a chronic autoantibody disease with a high…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Pfizer Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
